Personalis
Fremont, California, United States · Bioinformatics, Biotechnology, Genetics
Personalis, Inc. (NASDAQ: PSNL) is a company focused on transforming the active management of cancer through personalized testing, guiding care from diagnosis through treatment.
Key facts
- Headquarters
- Fremont, California, United States
- Employees
- 429
- Industries
- Bioinformatics, Biotechnology, Genetics
- Status
- Public (PSNL)
- Website
- personalis.com
- Company page
Recent activity at Personalis
- : Personalis, Inc. Secures New Task Order with U.S. Department of Veterans Affairs (date Fundz recorded it)
- : Personalis Promotes Dr. Richard Chen to President and CMO
- : SEC 8-K (8.01): On October 2, 2026, the Hart-Scott-Rodino (HSR) waiting period for the merger between Personalis, Inc. and Tempus AI, Inc. expired, allowing the transactions to proceed. This merger involves Personalis being acquired by Tempus, with two mergers taking place where Personalis will become a wholly owned subsidiary of Tempus. The expiration of the HSR waiting period is a critical step towards closing the merger, which is subject to further conditions, including stockholder approval to be determined at an upcoming virtual stockholders meeting. The overall strategic impact is significant as it combines the strengths of both companies in the cancer management space.
- : SEC 8-K (8.01): On August 20, 2026, Personalis, Inc. entered into a new task order under its existing contract with the U.S. Department of Veterans Affairs for the Million Veteran Program. This task order, with a potential value of up to $18.3 million, is effective from September 30, 2026, contingent upon the receipt of samples from the VA MVP and performance of services by Personalis. The additional task order raises the total cumulative value of Personalis' contracts with the VA MVP to approximately $243.3 million, indicating a significant expansion in their business relationship with the VA.
- : SEC 8-K (7.01): On July 20, 2026, the Company and Tempus announced the entry into a Merger Agreement for a proposed business combination. The agreement involves two mergers: first, Tempus’s wholly-owned subsidiary, Merger Sub I, will merge with the Company, making it a direct subsidiary of Tempus, and subsequently, the Company will merge into another subsidiary, Merger Sub II, which will survive as a direct subsidiary of Tempus. This strategic move is expected to consolidate operations and drive future synergies. Key parties involved are the Company, Tempus, and their respective subsidiaries, with significant implications for both organizations' market positions and operational efficiencies.
- : SEC 8-K (1.01): On July 20, 2026, Personalis, Inc. entered into a Merger Agreement with Tempus AI, Inc., involving a two-step merger where Merger Sub I will first merge with Personalis, making it a wholly-owned subsidiary of Tempus, followed immediately by Merger Sub II merging with the surviving entity. The transaction is structured to qualify as a reorganization under Section 368(a) of the Code. The boards of directors of both Personalis and Tempus have approved the agreement, which includes provisions for stockholder considerations during the Effective Time, ensuring that those shares will convert to shares of Tempus's Class A Common Stock based on an Exchange Ratio detailed in the agreement. This strategic merger aims to enhance the operational capacities and market reach of the combined companies.
- : SEC 8-K (8.01): On May 19, 2026, the Centers for Medicare & Medicaid Services expanded Medicare coverage for Personalis, Inc.’s ultrasensitive NeXT Personal ® test. This expansion includes monitoring treatment response to neoadjuvant therapy (NAT) in patients diagnosed with Stage II-III Triple-Negative Breast Cancer (TNBC) or HER2-positive (HER2+) breast cancer. This coverage change is expected to significantly impact the accessibility of advanced diagnostic services for patients undergoing treatment, thereby potentially improving clinical outcomes. The details of this coverage change are crucial for stakeholders in the healthcare sector, particularly those involved in oncology diagnostics.
- : SEC 8-K (8.01): On May 12, 2026, the Centers for Medicare & Medicaid Services expanded Medicare coverage for Personalis, Inc.'s ultrasensitive NeXT Personal ® test to include immunotherapy monitoring specifically targeting patients with late-stage solid tumors. This expansion potentially increases the market reach of the NeXT Personal test, allowing broader access for patients who require immunotherapy, thus enhancing the company's positioning in the molecular diagnostics sector. The decision by CMS is significant as it aligns with ongoing trends towards personalized medicine, and may lead to increased reimbursement opportunities for the affected tests. The filing was reported by Personalis, Inc. on May 13, 2026.
- : SEC 8-K (5.02): On March 13, 2026, Personalis, Inc. appointed Richard Chen as the Company’s President, succeeding Christopher Hall, who previously held the position. Dr. Chen, who has been with the Company since March 2023 as Executive Vice President of R&D and is a member of the clinical faculty at Stanford University, will see his annual base salary increase to $570,000 effective April 1, 2026. In addition, he will receive a performance bonus target of 70% of his salary and equity awards that include an option to purchase 37,500 shares of common stock and a restricted stock unit award for 6,250 shares, both subject to specific vesting conditions. This change reflects a strategic move to bolster leadership as the Company continues to advance in its R&D efforts.
- : SEC 8-K (8.01): On November 28, 2025, Personalis, Inc. filed a prospectus supplement under its existing shelf registration statement, offering up to $100,000,000 in shares of its common stock. This move involves the Amended and Restated At-the-Market Sales Agreement executed on December 27, 2024, with Piper Sandler & Co. and BTIG, LLC. The new offering is intended to enhance capital raising efforts and expand the market presence of the company, thereby providing strategic liquidity for operational needs and growth initiatives. The prospectus supplement is integral to ongoing financing strategies and is supported by the legal opinion from Cooley LLP included as an exhibit to the filing.
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
Personalis funding history
| Date | Round | Amount |
|---|---|---|
| Jul 2017 | Venture | $12.2M |
Leadership
- Jenevieve Fisher, Regional Director of Sales, Director of Pediatric Initiatives
- Vincent Miles, Director
- Ken Ludlum, Director
- Patrick Balthrop, Director
- Jonathan MacQuitty, Director
- Chris Schaepe, Director
- John West, Executive Officer, Director
- Richard Chen, Chief Medical Officer
- Carol Tillis, Executive Officer
Verified email and direct lines for Personalis’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Employee benefit plans
Personalis files 6 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Personalis in the news
- Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great Britain - Business Wire (Jul 14, 2026)
- Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits - Business Wire (Jun 09, 2026)
- Mayo Clinic collaborates with Personalis Inc. to expand cancer genomic testing - Mayo Clinic News Network (Oct 12, 2021)
- Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors - Business Wire (May 13, 2026)
- Personalis, Inc. (PSNL) Company Information - Simply Wall St (Aug 08, 2022)
- Personalis Reports Second Quarter Results and Recent Highlights - Business Wire (Aug 04, 2026)
- Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring - Business Wire (May 20, 2026)
- Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026 - Business Wire (Jun 02, 2026)
Companies similar to Personalis
- Akoya Biosciences · Bioinformatics, Biotechnology, Genetics, Health Care, Health Diagnostics
- GenePlanet · Bioinformatics, Biotechnology, Genetics, Health Care, Health Diagnostics
- Genoox · Bioinformatics, Biotechnology, Genetics, Health Care, Health Diagnostics
- Genomic Testing Cooperative · Bioinformatics, Biotechnology, Genetics, Health Care, Health Diagnostics
- Breakthrough Genomics · Bioinformatics, Biotechnology, Genetics, Health Care, Health Diagnostics
About Personalis: questions and answers
What does Personalis do?
Personalis, Inc. (NASDAQ: PSNL) is a company focused on transforming the active management of cancer through personalized testing, guiding care from diagnosis through treatment.
Where is Personalis headquartered?
Personalis is headquartered in Fremont, California, United States.
How many employees does Personalis have?
Personalis has about 429 employees.
Has Personalis raised funding?
Yes. Fundz has recorded 1 funding event for Personalis. The most recent, $12.2M, was in Jul 2017.
What is the latest news on Personalis?
On Aug 20, 2026, Personalis, Inc. Secures New Task Order with U.S. Department of Veterans Affairs
Is Personalis a public company?
Yes. Personalis is publicly traded under the ticker PSNL.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy